DK1628530T3 - Fremgangsmåder og sammensætninger til forebyggelse og behandling af sepsis - Google Patents

Fremgangsmåder og sammensætninger til forebyggelse og behandling af sepsis

Info

Publication number
DK1628530T3
DK1628530T3 DK04752211.5T DK04752211T DK1628530T3 DK 1628530 T3 DK1628530 T3 DK 1628530T3 DK 04752211 T DK04752211 T DK 04752211T DK 1628530 T3 DK1628530 T3 DK 1628530T3
Authority
DK
Denmark
Prior art keywords
sepsis
prevention
compositions
treatment
methods
Prior art date
Application number
DK04752211.5T
Other languages
English (en)
Inventor
Tom Eirik Mollnes
Sek Chung Fung
Original Assignee
Genentech Inc
Medinnova As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc, Medinnova As filed Critical Genentech Inc
Application granted granted Critical
Publication of DK1628530T3 publication Critical patent/DK1628530T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
DK04752211.5T 2003-05-15 2004-05-14 Fremgangsmåder og sammensætninger til forebyggelse og behandling af sepsis DK1628530T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47068103P 2003-05-15 2003-05-15
PCT/US2004/015135 WO2004103294A2 (en) 2003-05-15 2004-05-14 Methods and compositions for the prevention and treatment of sepsis

Publications (1)

Publication Number Publication Date
DK1628530T3 true DK1628530T3 (da) 2012-07-23

Family

ID=33476736

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04752211.5T DK1628530T3 (da) 2003-05-15 2004-05-14 Fremgangsmåder og sammensætninger til forebyggelse og behandling af sepsis

Country Status (10)

Country Link
US (1) US8329169B2 (da)
EP (2) EP2266606B1 (da)
JP (2) JP4768620B2 (da)
CN (2) CN102258784A (da)
AU (2) AU2004241069B2 (da)
CA (1) CA2524534C (da)
DK (1) DK1628530T3 (da)
ES (2) ES2522525T3 (da)
MX (1) MXPA05011886A (da)
WO (1) WO2004103294A2 (da)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8080245B2 (en) * 2004-08-04 2011-12-20 University Of Massachusetts Anti-pathogen immunoadhesins
AU2005313971B2 (en) * 2004-12-08 2011-10-13 Immunomedics, Inc. Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer
WO2008154018A2 (en) * 2007-06-11 2008-12-18 The Trustees Of The University Of Pennsylvania Properdin modulation of alternative pathway and uses thereof
US20110190221A1 (en) * 2008-03-28 2011-08-04 Apellis Ag Modulation and repletion/enhancement of the complement system for treatment of trauma
WO2010135717A2 (en) 2009-05-21 2010-11-25 Potentia Pharmaceuticals, Inc. Complement assays and uses thereof
CA2766565A1 (en) 2009-06-23 2010-12-29 Alexion Pharmaceuticals, Inc. Bispecific antibodies that bind to complement proteins
EP2309001A1 (de) * 2009-09-23 2011-04-13 SIRS-Lab GmbH Verfahren zur in vitro Erfassung und Unterscheidung von pathophysiologischen Zuständen
US9358266B2 (en) * 2010-02-25 2016-06-07 The Trustees Of The University Of Pennsylvania Treatment of sepsis using complement inhibitors
CA2811221C (en) * 2010-03-10 2018-01-09 Novelmed Therapeutics, Inc. Humanized and chimeric anti-properdin antibodies
MX340696B (es) * 2010-04-30 2016-07-21 Alexion Pharma Inc Anticuerpos anti-c5a y metodos para usar los anticuerpos.
US9120838B2 (en) 2011-04-18 2015-09-01 Curators Of The University Of Missouri Saccharide conjugates
JP5793188B2 (ja) 2011-05-13 2015-10-14 国立大学法人 東京大学 自己免疫疾患治療及び予防薬としてのｃｔｒｐ６
RU2723554C2 (ru) * 2011-05-19 2020-06-16 Мотида Фармасьютикал Ко., Лтд. Диагностика инфекционного заболевания дыхательных путей с использованием образцов крови
KR20140064768A (ko) 2011-07-01 2014-05-28 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 항-프로퍼딘 항체 및 그의 용도
CN102363781A (zh) * 2011-10-19 2012-02-29 海南大学 一种有效抑制小鼠mCD14基因表达的小干扰核糖核酸分子
CN102533758B (zh) * 2011-10-19 2014-04-02 海南大学 一种抑制水牛膜分化抗原14 基因表达的小核糖核酸分子
ES2728278T3 (es) 2011-12-21 2019-10-23 Novartis Ag Composiciones que comprenden anticuerpos dirigidos al factor P y C5
EP3722320A3 (en) 2012-10-25 2020-12-30 Bioverativ USA Inc. Anti-complement c1s antibodies and uses thereof
DK2914291T3 (da) 2012-11-02 2022-05-16 Bioverativ Usa Inc Anti-komplement-c1s-antistoffer og anvendelser deraf
EP2997045A4 (en) * 2013-05-15 2016-11-23 Annexon Inc ANTI-FACTOR C1S ANTIBODIES OF THE COMPLEMENT AND USES THEREOF
DK3019240T3 (da) 2013-07-09 2024-06-03 Annexon Inc Anti-komplementfaktor C1Q antistoffer og anvendelser deraf
SI3011345T1 (sl) 2013-08-07 2017-12-29 Alexion Pharmaceuticals, Inc. Biomarkerski proteini za atipični hemolitični uremični sindrom (ahus)
US20150104445A1 (en) * 2013-10-10 2015-04-16 Viropharma Holdings Limited Methods of inhibiting the alternative pathway of complement immune system activation and compositions used therein
WO2015078711A2 (en) * 2013-11-18 2015-06-04 Westfaelische Wilhelms-Universitaet Muenster Methods, peptides and antibodies for preventing, treating and diagnosing an inflammatory condition
WO2015140591A1 (en) * 2014-03-21 2015-09-24 Nordlandssykehuset Hf Anti-cd14 antibodies and uses thereof
EP3973994A1 (en) 2014-06-12 2022-03-30 RA Pharmaceuticals, Inc. Modulation of complement activity
SI3215527T1 (sl) 2014-11-05 2025-04-30 Annexon, Inc. Humanizirana protitelesa proti komplementnemu faktorju C1q in njihova uporaba
US20160168237A1 (en) * 2014-12-12 2016-06-16 Alexion Pharmaceuticals, Inc. Method for treating a complement mediated disorder caused by an infectious agent in a patient
US9937222B2 (en) 2015-01-28 2018-04-10 Ra Pharmaceuticals, Inc. Modulators of complement activity
CA2981321A1 (en) 2015-04-06 2016-10-13 True North Therapeutics, Inc. Humanized anti-c1s antibodies and methods of use thereof
US10975131B2 (en) 2015-10-27 2021-04-13 University Of Massachusetts Factor H-Fc immunotheraphy
EP3380518B1 (en) 2015-11-24 2026-03-25 Annexon, Inc. Anti-complement factor c1q fab fragments and uses thereof
RU2733720C2 (ru) 2015-12-16 2020-10-06 Ра Фармасьютикалз, Инк. Модуляторы активности комплемента
WO2017134043A1 (en) * 2016-02-01 2017-08-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for neutralising the cytotoxic activity of extracellular histone proteins in subjects suffering from sepsis
CN110300520B (zh) 2016-10-12 2022-10-04 美国比奥维拉迪维股份有限公司 抗C1s抗体及其使用方法
KR20190093196A (ko) 2016-12-07 2019-08-08 라 파마슈티컬스 인코포레이티드 보체 활성의 조절인자
CN111683672A (zh) 2017-12-04 2020-09-18 Ra制药公司 补体活性调节剂
GB201800620D0 (en) 2018-01-15 2018-02-28 Univ Manchester C3b Binding Polypeptide
WO2020011869A2 (en) 2018-07-11 2020-01-16 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides targeting tlr2
TW202100179A (zh) 2019-03-08 2021-01-01 美商Ｒａ製藥公司 補體活性之調節劑
TW202102481A (zh) 2019-03-29 2021-01-16 美商Ｒａ製藥公司 補體調節劑和相關方法
SG11202109837SA (en) 2019-04-24 2021-10-28 Ra Pharmaceuticals Inc Compositions and methods for modulating complement activity
JP2022535411A (ja) 2019-06-04 2022-08-08 ラ ファーマシューティカルズ インコーポレイテッド 補体阻害剤による炎症性疾患治療
US12486322B2 (en) 2021-12-13 2025-12-02 Annexon, Inc. Anti-complement factor C1q antibodies with single binding arms and uses thereof

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
ES2054667T3 (es) 1986-04-28 1994-08-16 Cetus Oncology Corp Anticuerpos monoclonales contra c5a y des-arg74-c5a, su produccion y uso.
US5093117A (en) 1989-01-24 1992-03-03 Baxter International Inc. Compositions and method for the treatment or prophylaxis of sepsis or septic shock
DK0485430T3 (da) 1989-08-01 1999-06-14 Scripps Research Inst Fremgangsmåder og sammensætninger til bedring af symptomer på sepsis
US6315999B1 (en) * 1989-08-10 2001-11-13 Solvay, S.A. Pharmaceutical product for the treatment of sepsis
DE4029227A1 (de) 1990-09-14 1992-03-19 Imtox Gmbh Arzneimittel enthaltend cd14
AU2694592A (en) 1991-09-30 1993-05-03 Walser, Mackenzie Methods for treatment of free-radical-mediated tissue injury
EP0634935A4 (en) 1992-04-06 1996-01-31 North Shore Univ Hospital A NEW THERAPY OF SEPSIS BY MEANS OF A SOLUBLE FORM OF RECOMBINANT CD14 MYELOMONOCYTIC ANTIGEN.
US6063764A (en) 1992-06-01 2000-05-16 Washington University & Chiron Corp. Method for using lipoprotein associated coagulation inhibitor to treat sepsis
US5330754A (en) * 1992-06-29 1994-07-19 Archana Kapoor Membrane-associated immunogens of mycobacteria
EP0682526B1 (en) 1993-02-12 2002-09-04 Avant Immunotherapeutics, Inc. PULMONARY ADMINISTRATION OF THE SOLUBLE COMPLEM RECEPTOR TYPE 1 sCR1
US5820858A (en) 1993-05-28 1998-10-13 The Scripps Research Institute Methods and compositions for inhibiting CD14 mediated cell activation
AU686816B2 (en) * 1994-07-05 1998-02-12 Steeno Research Group A/S Immunomodulators
ATE308994T1 (de) 1994-09-16 2005-11-15 Scripps Research Inst Gebrauch von antikörpern zur verhinderung von auswirkungen hervorgerufen durch grampositive- und myko-bakterien
JPH10511652A (ja) * 1994-12-23 1998-11-10 ラボラトワール・オン・ソシエテ・アノニム 炎症性疾患の予防および／または治療に対するｍｈｃ−ｉｉ結合および／またはｍｈｃ−ｉｉ模倣分子の使用
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6042821A (en) 1995-11-21 2000-03-28 Smithkline Beecham Corporation Method of treating sepsis with chemokines
US6290948B1 (en) 1996-05-14 2001-09-18 Smithkline Beecham Corporation Method of treating sepsis and ARDS using chamohine beta-10
ATE196091T1 (de) * 1996-05-22 2000-09-15 Univ Alberta Typ-2 chemokine-bindende proteine und verfahren zu deren verwendung
AU3048797A (en) 1996-10-22 1998-05-15 Chugai Seiyaku Kabushiki Kaisha Sepsis remedy comprising anti-il-8 antibody as active ingredient
US6172220B1 (en) 1997-01-21 2001-01-09 Board Of Regents Of University Of Nebraska Isolated algal lipopolysaccharides and use of same to inhibit endotoxin-initiated sepsis
CA2253877A1 (en) 1997-03-07 1998-11-09 Mochida Pharmaceutical Co., Ltd. Antisense compounds to cd14
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
HUP0001237A3 (en) 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
ID26730A (id) 1998-05-27 2001-02-01 Gemma Biotechnology Ltd Induksi protein-protein dan peptida-peptida antibiotik oleh lait/scd14-protein
EP1115875A1 (en) * 1998-09-24 2001-07-18 Regents Of The University Of Minnesota Human complement c3-degrading polypeptide from streptococcus pneumoniae
CN1324244A (zh) * 1998-10-22 2001-11-28 伊莱利利公司 治疗脓毒症的方法
US20030114377A1 (en) 1998-11-18 2003-06-19 Kirkland Theo N. Inhibition therapy for septic shock with mutant CD14
DE19913707A1 (de) * 1999-03-26 2000-10-05 Privates Inst Bioserv Gmbh Immunadsorber zur Sepsistherapie
JP4489976B2 (ja) * 1999-04-09 2010-06-23 ビーエーエスエフ ソシエタス・ヨーロピア 補体プロテアーゼの低分子インヒビター
CA2373942A1 (en) * 1999-05-18 2000-11-23 Teijin Limited Remedies or prophylactis for diseases in association with chemokines
US6673346B1 (en) * 1999-08-31 2004-01-06 The Regents Of The University Of Michigan Compositions and methods for the treatment of sepsis
CA2400488A1 (en) * 2000-02-08 2001-08-16 The University Of Virginia Patent Foundation Methods for the prevention and treatment of infections using anti-c3b(i) antibodies
US20020006915A1 (en) 2000-02-15 2002-01-17 Mack Strong Vivian E. Use of COX-2 inhibitors to treat sepsis, complications thereof, and EP receptor modulation
CA2404511A1 (en) 2000-03-31 2001-10-04 Mochida Pharmaceutical Co., Ltd. Tlr/cd14 binding inhibitor
US20040092712A1 (en) 2000-03-31 2004-05-13 Shoji Furusako Tlr/cd14 binding inhibitor
JP5260818B2 (ja) 2000-09-29 2013-08-14 ノバルティス・インターナショナル・ファーマシューティカル・リミテッド 高親和性低分子Ｃ５ａ受容体調節物質
AU2001290315A1 (en) 2000-11-22 2002-06-03 Mochida Pharmaceutical Co., Ltd. Anti-cd14 monoclonal antibody having effect of inhibiting cd14/tlr binding
KR20030074693A (ko) 2000-12-28 2003-09-19 알투스 바이올로직스 인코포레이티드 전항체 및 이의 단편의 결정과 이의 제조 및 사용 방법
US20030077576A1 (en) * 2001-03-20 2003-04-24 Joann Trial Use of monoclonal antibodies and functional assays for prediction of risk of opportunistic infection
EP1425028B1 (en) 2001-05-16 2009-12-16 Yeda Research And Development Co. Ltd. Use of il-18 inhibitors for the treatement or prevention of sepsis
ES2283594T5 (es) * 2001-08-17 2016-03-15 Genentech, Inc. Inhibidores de la ruta del complemento que se unen a C5 y C5a sin impedir la formación de C5b
US20060140939A1 (en) * 2003-02-21 2006-06-29 Fung Sek C M Methods for preventing and treating tissue damage associated with ischemia-reperfusion injury

Also Published As

Publication number Publication date
WO2004103294A3 (en) 2005-05-26
HK1152474A1 (en) 2012-03-02
EP2266606A1 (en) 2010-12-29
CA2524534C (en) 2012-12-11
EP1628530A4 (en) 2007-08-29
EP2266606B1 (en) 2014-09-10
ES2387275T3 (es) 2012-09-19
AU2010249190B2 (en) 2013-02-28
ES2522525T3 (es) 2014-11-14
EP1628530A2 (en) 2006-03-01
US20070274989A1 (en) 2007-11-29
EP1628530B8 (en) 2012-08-01
CA2524534A1 (en) 2004-12-02
JP2006528981A (ja) 2006-12-28
CN1787741A (zh) 2006-06-14
EP1628530B1 (en) 2012-06-06
JP2011105747A (ja) 2011-06-02
AU2004241069A1 (en) 2004-12-02
CN102258784A (zh) 2011-11-30
AU2004241069B2 (en) 2010-09-09
US8329169B2 (en) 2012-12-11
CN1787741B (zh) 2011-08-17
MXPA05011886A (es) 2006-02-17
JP4768620B2 (ja) 2011-09-07
WO2004103294A2 (en) 2004-12-02
AU2010249190A1 (en) 2011-01-06

Similar Documents

Publication Publication Date Title
DK1628530T3 (da) Fremgangsmåder og sammensætninger til forebyggelse og behandling af sepsis
DK1644021T3 (da) Fremgangsmåder og sammensætninger til behandlingen af gastrointestinale sygdomme
DK1667986T3 (da) Acetonesolvat af dimethoxydocetaxel og fremgangsmåde til fremstilling heraf
DK1791791T3 (da) Fremgangsmåder og sammensætninger til behandling af vand
NO20055837D0 (no) Immunsupprimerende forbindelser og sammensetninger
DK3159357T3 (da) Sammensætning og fremgangsmåde til behandling og forebyggelse af enteriske bakterielle infektioner
DK1830838T3 (da) Sammensætninger og fremgangsmåder til behandling af neoplastiske sygdomme
DK1506041T3 (da) Inbandronsyre til behandling og forebyggelse af osteoporose
DK1888033T3 (da) Fremgangsmåde og sammensætning til behandling af inflammatoriske sygdomme
DK1831154T3 (da) Fremstilling af pregabalin og relaterede forbindelser
DK1891571T3 (da) Hæmning af spredning af uønskede koder og data
DK2072051T3 (da) Kombination af azelastin og mometason
DK1638999T3 (da) Sammensætninger og fremgangsmåder til øgning af knoglemineralisering
DK1824475T3 (da) Fremgangsmåde til oprensning af trans-(-)-delta9-tetrahydrocannabinol og trans-(+)-delta9-tetrahydrocannabinol
DK1948234T3 (da) Sammensætninger og fremgangsmåder til behandling og forebyggelse af fibrotiske, inflammatoriske og neovaskulære tilstande
DK1679058T3 (da) Farmaceutisk sammensætning til behandling af kardiovaskulære og cerebrovaskulære sygdomme
DK1587821T6 (da) Sammensætninger og fremgangsmåder til stabilisering af trans-thyretin og inhibering af transthyretin-fejlfoldning
NO20044148L (no) Sammensetning og fremgangsmate for bronnrensing
DK1592686T3 (da) Gyrase-inhibitorer og anvendelser deraf
DK1677735T3 (da) Fremgangsmåder og sammensætninger til modulering af adipocytfunktion
DK1805312T3 (da) Fremgangsmåder og midler til fremstilling af hyaluronan
DK1667730T3 (da) Sammensætninger og fremgangsmåder til behandling af inflammatorisk lungesygdom
DK1830924T3 (da) Forebyggelse af thrombedannelse og/eller -stabilisering
DK1771201T3 (da) Sammensætninger og fremgangsmåder til behandling eller forebyggelse af oxalat-relateret sygdom
DK1858488T4 (da) Tigecyclinsammensætninger og fremgangsmåder til fremstilling deraf